[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:erbb2-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"ERBB2 Gene",127,116,[8,16,23,30,36,42,48,53,59,65,71,77,84,90,96,102,108,114,120,126,132,138,144,150,156,162,167,172,178,184,190,196,201,206,212,218,224,230,236,242,248,254,259,265,271,277,283,289,295,301],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07205822","A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer",[12],"Phase 3","RECRUITING","2026-08-26T02:16:16.169331Z","2026-07-30T01:46:14.435695Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07102381","A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer",[20],"Phase 2","2026-08-26T02:18:23.582895Z","2026-07-05T05:32:16.733599Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07198724","ERADICATE: A Phase Ib\u002FII Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4\u002F6 Inhibitor and Endocrine-resistant HR+\u002FHER2-low or HER2-ultralow Metastatic Breast Cancer",[27],"Phase 1\u002FPhase 2","2026-08-26T02:18:00.873391Z","2026-07-05T05:32:16.660998Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07407920","Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial",[20],"2026-08-26T02:18:19.586423Z","2026-07-05T03:45:20.251405Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07022483","Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+\u002F2+) Endometrial Cancer",[12],"2026-08-26T02:16:12.203827Z","2026-05-05T02:43:29.698094Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06185205","ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy",[20],"2026-08-26T02:17:02.694423Z","2026-05-05T02:43:29.681174Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":21,"content_modified":52},"NCT06263543","Sequencing Antibody Drug Conjugates in ER+\u002FHER2 LOW\u002FULTRA LOW MBC",[20],"2026-05-05T02:43:29.578585Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT07053085","A Study of Surgery and Radiotherapy in People With Breast Cancer",[20],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:29.533955Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT05035836","A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2\u002FNeu Positive (HER2+) Breast Cancer (BC)",[20],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:29.502984Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT04893109","ATEMPT 2.0: Adjuvant T-DM1 vs TH",[20],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:29.497520Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT03769415","Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA",[],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:29.398737Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":82,"content_modified":83},"NCT04144023","A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ",[81],"Phase 1","2026-08-26T02:16:49.565137Z","2026-05-05T02:43:29.361204Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT04886531","Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers",[20],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:29.351520Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT05672524","A Study of Tucatinib and Trastuzumab in People With Rectal Cancer",[20],"2026-08-26T02:17:00.709807Z","2026-05-05T02:43:29.285490Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT03803553","Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",[12],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:29.200175Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT01042379","I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer",[20],"2026-08-26T02:19:28.327680Z","2026-05-05T02:43:29.200132Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06764875","A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer",[12],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:29.164625Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT05379595","A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",[27],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:29.076898Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT06241456","FT825\u002FONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors",[81],"2026-08-26T02:18:32.765187Z","2026-05-05T02:43:29.070504Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT06043817","First-In-Human Study of STX-721\u002FPFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations",[27],"2026-08-26T02:17:55.355429Z","2026-05-05T02:43:29.021992Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT05774678","Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation",[12],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:29.021355Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT02491099","A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma",[20],"2026-08-26T02:15:18.897219Z","2026-05-05T02:43:28.811453Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT06282575","Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer",[12],"2026-08-26T02:18:53.782384Z","2026-05-05T02:43:28.646214Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT02945579","Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy",[],"2026-08-26T02:17:56.243868Z","2026-05-05T02:43:28.564466Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT06989112","DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+\u002F2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer",[12],"2026-08-26T02:16:09.452956Z","2026-05-05T02:43:28.516336Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":21,"content_modified":166},"NCT07228247","A Phase Ⅰ\u002FⅡa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors",[27],"2026-05-05T02:43:28.487784Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":69,"content_modified":171},"NCT06072612","Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.",[12],"2026-05-05T02:43:28.478069Z",{"nct_id":173,"title":174,"phases":175,"status":13,"updated_at":176,"content_modified":177},"NCT06253494","Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer",[27],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:28.474793Z",{"nct_id":179,"title":180,"phases":181,"status":13,"updated_at":182,"content_modified":183},"NCT07012031","Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation",[27],"2026-08-26T02:16:11.347936Z","2026-05-05T02:43:28.418568Z",{"nct_id":185,"title":186,"phases":187,"status":13,"updated_at":188,"content_modified":189},"NCT07506876","Concurrent Neoadjuvant Chemo\u002FEndocrine Therapy in HER2+ Breast Cancer",[20],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:28.342526Z",{"nct_id":191,"title":192,"phases":193,"status":13,"updated_at":194,"content_modified":195},"NCT06819007","Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)",[12],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:28.293021Z",{"nct_id":197,"title":198,"phases":199,"status":13,"updated_at":176,"content_modified":200},"NCT04553770","Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer",[20],"2026-05-05T02:43:28.285926Z",{"nct_id":202,"title":203,"phases":204,"status":13,"updated_at":148,"content_modified":205},"NCT05950945","Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer",[12],"2026-05-05T02:43:28.282790Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT05957536","A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors",[81],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:28.210943Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":216,"content_modified":217},"NCT05673928","A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)",[20],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:28.183681Z",{"nct_id":219,"title":220,"phases":221,"status":13,"updated_at":222,"content_modified":223},"NCT06876714","ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab",[12],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:28.130354Z",{"nct_id":225,"title":226,"phases":227,"status":13,"updated_at":228,"content_modified":229},"NCT06745908","Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In",[12],"2026-08-26T02:18:42.501841Z","2026-05-05T02:43:28.120702Z",{"nct_id":231,"title":232,"phases":233,"status":13,"updated_at":234,"content_modified":235},"NCT06311214","Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)",[20],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:28.118704Z",{"nct_id":237,"title":238,"phases":239,"status":13,"updated_at":240,"content_modified":241},"NCT06532006","A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer",[12],"2026-08-26T02:17:06.985283Z","2026-05-05T02:43:28.114299Z",{"nct_id":243,"title":244,"phases":245,"status":13,"updated_at":246,"content_modified":247},"NCT05681780","Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC",[81],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:27.992106Z",{"nct_id":249,"title":250,"phases":251,"status":13,"updated_at":252,"content_modified":253},"NCT06441890","BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer",[20],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:27.988655Z",{"nct_id":255,"title":256,"phases":257,"status":13,"updated_at":106,"content_modified":258},"NCT06897488","EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial",[20],"2026-05-05T02:43:27.982803Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":263,"content_modified":264},"NCT05020860","Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer",[20],"2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.962723Z",{"nct_id":266,"title":267,"phases":268,"status":13,"updated_at":269,"content_modified":270},"NCT07195695","Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment",[12],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:27.661184Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":275,"content_modified":276},"NCT06340568","A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer",[12],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:27.635834Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":281,"content_modified":282},"NCT07428044","A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer",[20],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:27.588648Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":287,"content_modified":288},"NCT05232916","Phase 3 Study to Evaluate the Efficacy and Safety of HER2\u002FNeu Peptide GLSI-100 (GP2 + GM-CSF) in HER2\u002FNeu Positive Subjects",[12],"2026-08-26T02:17:30.961790Z","2026-05-05T02:43:27.514719Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":293,"content_modified":294},"NCT05325632","Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab",[20],"2026-08-26T02:18:44.395098Z","2026-05-05T02:43:27.513782Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":299,"content_modified":300},"NCT06533826","TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd",[20],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:27.433128Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":305,"content_modified":306},"NCT06439693","The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer",[20],"2026-08-26T02:17:39.857430Z","2026-05-05T02:43:27.429305Z"]